 |
| Ligand ID: CL6 Drugbank ID: DB00257(Clotrimazole) Indication:For the local treatment of oropharyngeal candidiasis and vaginal yeast infections, also used in fungal infections of the skin such as ringworm, athlete's foot, and jock itch. |
| DrReposER ID / Desc. | Hit PDBID |
Hit Macromolecule |
Res. Matches |
View | Interface | RMSD | Seq. Identity (%) |
HETATM | Dock | |
|---|---|---|---|---|---|---|---|---|---|---|
 Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 8 | LEU A 250ILE A 249THR A 201LEU A 205 | 1.62A | 15.25 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 5 | LEU A 250ALA A 255VAL A 212ILE A 213 | 1.60A | 20.35 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 8 | LEU A 227GLN A 244THR A 225LEU A 262 | 1.54A | 15.25 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 8 | GLN A 244ILE A 249THR A 201LEU A 242 | 1.74A | 15.25 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 5 | LEU A 205THR A 257VAL A 212ILE A 213 | 1.62A | 20.35 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 89PHE A 66VAL A 20LEU A 58ILE A 43 | 1.48A | 15.37 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 8 | MET A 276LEU A 205LEU A 268LEU A 208 | 1.49A | 15.25 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | PHE A 219LEU A 282ILE A 281ALA A 206ALA A 210 | 1.75A | 15.37 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 8 | LEU A 208ILE A 281LEU A 287LEU A 268 | 1.26A | 15.25 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 205ILE A 259ALA A 260ALA A 266THR A 224 | 1.48A | 15.37 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 5 | LEU A 271ALA A 266VAL A 212ILE A 259 | 1.47A | 20.35 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 5 | LEU A 250ALA A 255VAL A 212ILE A 213 | 1.80A | 20.35 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 8 | LEU A 227GLN A 244LEU A 242LEU A 262 | 1.53A | 15.25 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 5 | LEU A 271ALA A 266THR A 225VAL A 233 | 1.79A | 20.35 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 9 | LEU A 89PHE A 66VAL A 20LEU A 58ILE A 43 | 1.49A | 15.37 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 8 | LEU A 208LEU A 268THR A 201LEU A 205 | 1.63A | 15.25 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 5 | LEU A 271ALA A 266VAL A 212ILE A 259 | 1.57A | 20.35 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 8 | MET A 165HIS A 164LEU A 57ILE A 43 | 1.43A | 15.25 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 8 | MET A 162HIS A 164ILE A 43LEU A 27 | 1.56A | 15.25 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 8 | HIS A 64LEU A 87ILE A 43LEU A 89 | 1.38A | 15.25 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 9 | LEU A 205ILE A 259ALA A 260ALA A 266THR A 224 | 1.49A | 15.37 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6lxt | SPIKE PROTEIN S2 (SARS-CoV-2) | 4 / 8 | LEU B 966ILE A1169LEU B 962LEU C 966 | 0.96A | 17.42 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 4 / 5 | LEU A 271ALA A 266VAL A 212ILE A 259 | 1.56A | 20.66 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 4 / 5 | LEU A 271ALA A 266VAL A 212ILE A 259 | 1.46A | 20.66 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 5 / 9 | LEU A 89PHE A 66VAL A 20LEU A 58ILE A 43 | 1.48A | 21.91 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 4 / 5 | LEU A 250ALA A 255VAL A 212ILE A 213 | 1.66A | 20.66 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 4 / 8 | LEU A 208ILE A 281LEU A 287LEU A 268 | 1.28A | 20.63 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 205LEU A 220ILE A 259ALA A 260THR A 224 | 1.44A | 21.91 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 4 / 5 | LEU A 205THR A 257VAL A 212ILE A 213 | 1.69A | 20.66 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 89PHE A 66VAL A 20LEU A 58ILE A 43 | 1.47A | 21.91 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 4 / 5 | LEU A 271ALA A 266VAL A 212ILE A 259 | 1.47A | 20.47 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 4 / 5 | LEU A 205THR A 257VAL A 212ILE A 213 | 1.69A | 20.47 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 4 / 5 | LEU A 271ALA A 266VAL A 212ILE A 259 | 1.58A | 20.47 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 5 / 9 | LEU A 89PHE A 66VAL A 20LEU A 58ILE A 43 | 1.46A | 21.87 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 5 / 9 | LEU A 205ILE A 259ALA A 260ALA A 266THR A 224 | 1.58A | 21.87 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 4 / 5 | LEU A 250ALA A 255VAL A 212ILE A 213 | 1.64A | 20.47 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 4 / 8 | LEU A 208ILE A 281LEU A 287LEU A 268 | 1.28A | 20.58 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 89PHE A 66VAL A 20LEU A 58ILE A 43 | 1.45A | 21.87 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 205ILE A 259ALA A 260ALA A 266THR A 224 | 1.56A | 21.87 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU B 89PHE B 66VAL B 20LEU B 58ILE B 43 | 1.50A | 21.89 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 5 | LEU C 205THR C 257VAL C 212ILE C 213 | 1.73A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 8 | LEU C 208ILE C 281LEU C 287LEU C 268 | 1.21A | 20.43 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 5 | LEU A 271ALA A 266VAL A 212ILE A 259 | 1.52A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 5 | LEU D 271ALA D 266VAL D 212ILE D 259 | 1.51A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 5 | LEU A 271ALA A 266VAL A 212ILE A 259 | 1.63A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 8 | LEU A 208ILE A 281LEU A 287LEU A 268 | 1.32A | 20.43 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 8 | LEU D 208ILE D 281LEU D 287LEU D 268 | 1.23A | 20.43 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 5 | LEU B 271ALA B 266VAL B 212ILE B 259 | 1.62A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 5 | ALA D 210THR D 257VAL D 261ILE D 259 | 1.51A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 9 | LEU D 89PHE D 66VAL D 20LEU D 58ILE D 43 | 1.47A | 21.89 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 5 | LEU A 250ALA A 255VAL A 212ILE A 213 | 1.66A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 5 | LEU C 250ALA C 255VAL C 212ILE C 213 | 1.66A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 9 | LEU B 205ILE B 259ALA B 260ALA B 266THR B 224 | 1.55A | 21.89 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 205LEU A 220ILE A 259ALA A 260THR A 224 | 1.50A | 21.89 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 9 | LEU A 89PHE A 66VAL A 20LEU A 58ILE A 43 | 1.51A | 21.89 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 205ILE A 259ALA A 260ALA A 266THR A 224 | 1.54A | 21.89 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU C 89PHE C 66VAL C 20LEU C 58ILE C 43 | 1.58A | 21.89 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 9 | LEU B 89PHE B 66VAL B 20LEU B 58ILE B 43 | 1.51A | 21.89 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 5 | LEU D 271ALA D 266VAL D 212ILE D 259 | 1.62A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 5 | LEU C 271ALA C 266VAL C 212ILE C 259 | 1.60A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 8 | LEU B 208ILE B 281LEU B 287LEU B 268 | 1.32A | 20.43 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU B 205LEU B 220ILE B 259ALA B 260THR B 224 | 1.52A | 21.89 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 9 | LEU A 205ILE A 259ALA A 260ALA A 266THR A 224 | 1.55A | 21.89 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 5 | ALA B 210THR B 257VAL B 261ILE B 259 | 1.38A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU D 89PHE D 66VAL D 20LEU D 58ILE D 43 | 1.46A | 21.89 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU B 205ILE B 259ALA B 260ALA B 266THR B 224 | 1.54A | 21.89 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 5 | ALA A 210THR A 257VAL A 261ILE A 259 | 1.40A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 5 | ALA C 210THR C 257VAL C 261ILE C 259 | 1.43A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 5 | LEU D 250ALA D 255VAL D 212ILE D 213 | 1.63A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 5 | LEU B 271ALA B 266VAL B 212ILE B 259 | 1.51A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 9 | LEU C 89PHE C 66VAL C 20LEU C 58ILE C 43 | 1.59A | 21.89 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 89PHE A 66VAL A 20LEU A 58ILE A 43 | 1.50A | 21.89 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 4 / 5 | LEU A 205THR A 257VAL A 212ILE A 213 | 1.65A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 205ILE A 259ALA A 260ALA A 266THR A 224 | 1.50A | 21.89 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 4 / 5 | LEU A 271ALA A 266VAL A 212ILE A 259 | 1.57A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 5 / 9 | LEU A 89PHE A 66VAL A 20LEU A 58ILE A 43 | 1.48A | 21.89 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 4 / 5 | LEU A 250ALA A 255VAL A 212ILE A 213 | 1.62A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 4 / 5 | LEU A 271ALA A 266VAL A 212ILE A 259 | 1.47A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 89PHE A 66VAL A 20LEU A 58ILE A 43 | 1.47A | 21.89 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 5 / 9 | LEU A 205ILE A 259ALA A 260ALA A 266THR A 224 | 1.51A | 21.89 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 4 / 8 | LEU A 208ILE A 281LEU A 287LEU A 268 | 1.24A | 20.43 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 4 / 5 | ALA A 210THR A 257VAL A 261ILE A 259 | 1.39A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 673THR A 538ILE A 539ALA A 376ALA A 382 | 1.12A | 19.77 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 8 | LEU A 575LEU A 638THR A 686LEU A 576 | 0.97A | 18.40 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 187LEU A 282ALA A 253THR A 252ALA A 250 | 1.53A | 19.77 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 576ALA A 690VAL A 587ILE A 757 | 1.54A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6m71 | NSP8 (SARS-CoV-2) | 4 / 5 | LEU B 98ALA B 102VAL B 115ILE B 119 | 1.65A | 19.75 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 245ALA A 185THR A 189VAL A 234 | 1.68A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6m71 | NSP12NSP8 (SARS-CoV-2) | 4 / 5 | LEU A 387ALA B 188VAL B 131ILE B 185 | 1.25A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6m71 | NSP7NSP8 (SARS-CoV-2) | 5 / 8 | MET D 90LEU D 103ILE D 107THR C 9LEU D 98 | 1.79A | 16.79 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 146ALA A 130VAL A 182ILE A 244 | 1.53A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 329ALA A 379VAL A 359ILE A 333 | 1.43A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 8 | HIS A 133LEU A 727GLN A 724LEU A 731 | 1.30A | 18.40 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6m71 | NSP12NSP8 (SARS-CoV-2) | 4 / 5 | LEU A 387ALA B 188VAL B 131ILE B 185 | 1.39A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 883LEU A 891ILE A 888ALA A 863ALA A 840 | 1.56A | 19.77 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 575ALA A 690VAL A 476ILE A 696 | 1.49A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 5 | ALA A 529THR A 531VAL A 373ILE A 536 | 1.60A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 186ALA A 250THR A 248VAL A 128 | 1.68A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6m71 | NSP8 (SARS-CoV-2) | 4 / 5 | LEU B 180ALA B 162VAL B 186ILE B 185 | 1.45A | 19.75 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 576ALA A 690VAL A 587ILE A 757 | 1.64A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 329ALA A 379VAL A 535ILE A 536 | 1.67A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6m71 | NSP8 (SARS-CoV-2) | 4 / 5 | LEU B 98ALA B 125THR B 123ILE B 119 | 1.42A | 19.75 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 8 | ILE A 244LEU A 241THR A 189LEU A 186 | 1.33A | 18.40 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6m71 | NSP8 (SARS-CoV-2) | 4 / 5 | LEU B 98ALA B 125THR B 123ILE B 119 | 1.42A | 19.75 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6m71 | NSP8 (SARS-CoV-2) | 4 / 5 | LEU B 180ALA B 162VAL B 186ILE B 185 | 1.47A | 19.75 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 8 | LEU A 245ILE A 244LEU A 241LEU A 186 | 1.12A | 18.40 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 146ALA A 130VAL A 182ILE A 244 | 1.64A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 576ALA A 581THR A 582VAL A 587 | 1.74A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 575ALA A 690VAL A 476ILE A 696 | 1.60A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 186ALA A 250THR A 248VAL A 128 | 1.69A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 329ALA A 379VAL A 359ILE A 333 | 1.34A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 5 | ALA A 250THR A 248VAL A 128ILE A 244 | 1.57A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 245ALA A 185THR A 189VAL A 234 | 1.62A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6m71 | NSP8 (SARS-CoV-2) | 4 / 5 | LEU B 98ALA B 125VAL B 115ILE B 119 | 1.47A | 19.75 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6m71 | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | LEU A 389ILE B 156ALA B 188ALA B 152THR B 148 | 1.51A | 19.77 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6m71 | NSP7NSP8 (SARS-CoV-2) | 4 / 8 | LEU D 95ILE D 107LEU C 56LEU D 91 | 1.01A | 16.79 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 5 | ALA A 250THR A 248VAL A 128ILE A 244 | 1.58A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6m71 | NSP12NSP8 (SARS-CoV-2) | 4 / 5 | LEU A 387THR B 141VAL B 131ILE B 132 | 1.70A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6m71 | NSP8 (SARS-CoV-2) | 4 / 5 | LEU B 98ALA B 125VAL B 115ILE B 119 | 1.45A | 19.75 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6vsb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 8 | LEU A 878ILE A 805LEU A 806THR A 791 | 0.89A | 14.95 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6vsb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 6 | HIS A 66ALA A 262ALA A 263THR A 95 | 1.21A | 14.95 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6vsb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 5 | LEU A 894ALA A 890VAL C 911ILE C 909 | 1.30A | 14.96 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6vxs | NSP3 (SARS-CoV-2) | 4 / 8 | LEU A 140ILE A 137LEU A 164LEU A 126 | 1.17A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6vxs | NSP3 (SARS-CoV-2) | 4 / 8 | LEU B 140ILE B 137LEU B 164LEU B 126 | 1.13A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6vxx | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 8 | LEU C 878ILE C 805LEU C 806THR C 791 | 0.85A | 15.19 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6vyb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 8 | LEU A 878ILE A 805LEU A 806THR A 791 | 0.83A | 15.19 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6vyb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 5 | LEU C 894ALA C 890VAL B 911ILE B 909 | 1.29A | 14.92 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w41 | SPIKE PROTEIN S1 (SARS-CoV-2) | 4 / 8 | LEU C 452GLN C 493THR C 470LEU C 492 | 1.48A | 16.06 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6w41 | SPIKE PROTEIN S1 (SARS-CoV-2) | 4 / 5 | LEU C 425ALA C 419VAL C 510ILE C 402 | 1.71A | 15.97 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6w41 | SPIKE PROTEIN S1 (SARS-CoV-2) | 4 / 5 | LEU C 425ALA C 419VAL C 510ILE C 402 | 1.57A | 15.97 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6w41 | SPIKE PROTEIN S1 (SARS-CoV-2) | 4 / 5 | LEU C 425THR C 376VAL C 510ILE C 434 | 1.43A | 15.97 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w41 | SPIKE PROTEIN S1 (SARS-CoV-2) | 5 / 12 | PHE C 400VAL C 512ILE C 402ALA C 411ALA C 419 | 1.50A | 15.27 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w41 | SPIKE PROTEIN S1 (SARS-CoV-2) | 5 / 12 | VAL C 407LEU C 513THR C 376ILE C 434ALA C 435 | 1.25A | 15.27 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w4b | NSP9 (SARS-CoV-2) | 4 / 6 | GLN A 21ALA A 16ALA A 55THR A 68 | 1.09A | 14.43 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w4b | NSP9 (SARS-CoV-2) | 6 / 12 | LEU B 70LEU B 49ALA B 23THR B 25ALA B 16ALA B 29 | 1.65A | 14.16 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w4h | NSP16 (SARS-CoV-2) | 4 / 6 | GLN A6957ALA A6960THR A6918PHE A6954 | 1.45A | 20.33 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 8 | LEU A7073ILE A7069LEU A7070LEU A6961 | 1.49A | 16.63 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 8 | LEU A7073ILE A7069LEU A7078THR A7055 | 1.79A | 16.63 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 6 | GLN A6957ALA A6960THR A6918PHE A6954 | 1.46A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 6 | GLN A6850ALA A6802THR A6993PHE A6991 | 1.53A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w61 | NSP10 (SARS-CoV-2) | 4 / 8 | LEU B4328ILE B4291THR B4364LEU B4365 | 1.61A | 16.63 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 8 | LEU A6883ILE A6926THR A6891LEU A6887 | 1.42A | 16.63 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 8 | HIS A6984LEU A7073ILE A7065LEU A7070 | 1.50A | 16.63 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 8 | LEU A7072ILE A7069LEU A7078THR A7055 | 1.70A | 16.63 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 8 | MET A6863LEU A6852ILE A6926LEU A6857 | 1.67A | 16.63 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 8 | LEU A7073ILE A7069LEU A7070LEU A7010 | 1.64A | 16.63 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | ILE A7080ALA A6960ALA A6858ALA A7056THR A7055 | 1.76A | 17.07 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 8 | HIS A6867ILE A7005LEU A6852LEU A6924 | 1.31A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | LEU A6857LEU A6848THR A6854THR A6989ALA A6966 | 1.68A | 17.07 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 8 | LEU A7073ILE A7065LEU A7070LEU A7010 | 1.55A | 16.63 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 8 | MET A6982LEU A6852LEU A6855THR A6989 | 1.80A | 16.63 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | LEU A6978THR A6970ILE A6969ALA A7002ALA A6966 | 1.69A | 17.07 | NoneKCX A6935 (-3.2A)NoneNoneNone | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | LEU A7072THR A7055ILE A7079ALA A6858ALA A6986 | 1.63A | 17.07 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 8 | LEU A7073ILE A7065LEU A6961LEU A7078 | 1.78A | 16.63 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 9 | LEU A7078ILE A7080ALA A6960ALA A7056THR A7055 | 1.41A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | LEU A7078ILE A7080ALA A6960ALA A7056THR A7055 | 1.42A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w61 | NSP10 (SARS-CoV-2) | 5 / 12 | LEU B4345THR B4309ILE B4308ALA B4307THR B4364 | 1.59A | 15.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 5 | LEU A6893THR A6918VAL A7086ILE A7088 | 1.80A | 15.63 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 8 | LEU A6883ILE A6926LEU A6924LEU A6887 | 1.69A | 16.63 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 8 | LEU A 208ILE A 281LEU A 287LEU A 268 | 1.19A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 5 | LEU A 271ALA A 266VAL A 212ILE A 259 | 1.47A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 9 | LEU A 89PHE A 66VAL A 20LEU A 58ILE A 43 | 1.49A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 5 | LEU A 205THR A 257VAL A 212ILE A 213 | 1.65A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 5 | LEU A 271ALA A 266VAL A 212ILE A 259 | 1.56A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 5 | ALA A 210THR A 257VAL A 261ILE A 259 | 1.37A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 89PHE A 66VAL A 20LEU A 58ILE A 43 | 1.48A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 9 | LEU A 205VAL A 247ILE A 259ALA A 266THR A 224 | 1.67A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 9 | LEU A 205ILE A 259ALA A 260ALA A 266THR A 224 | 1.60A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 5 | LEU A 250ALA A 255VAL A 212ILE A 213 | 1.59A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 8 | LEU A 140ILE A 18LEU A 153LEU A 126 | 1.58A | 16.87 | NoneNoneNoneAMP A 201 ( 4.4A) | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | LEU B 127VAL B 142LEU B 122THR B 146ALA B 124 | 1.56A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | VAL B 35ALA B 89ALA B 56ALA B 60THR B 57 | 1.64A | 17.82 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 8 | HIS B 119LEU B 43LEU B 75LEU B 83 | 1.39A | 16.87 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 8 | MET A 61HIS A 94LEU A 123ILE A 23 | 1.64A | 16.87 | NoneNoneNoneAMP A 201 ( 4.0A) | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | VAL A 35ALA A 89ALA A 56ALA A 60THR A 57 | 1.66A | 17.82 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 8 | HIS A 94ILE A 23THR A 57LEU A 88 | 1.39A | 16.87 | NoneAMP A 201 ( 4.0A)NoneNone | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 8 | ILE B 23LEU B 53THR B 57LEU B 88 | 1.65A | 16.87 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 8 | LEU A 140ILE A 137LEU A 164LEU A 126 | 1.30A | NoneNoneNoneAMP A 201 ( 4.4A) | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 8 | HIS A 119LEU A 43LEU A 75LEU A 83 | 1.40A | 16.87 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 8 | MET B 61HIS B 94LEU B 123ILE B 23 | 1.65A | 16.87 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 8 | LEU B 140ILE B 18LEU B 153LEU B 126 | 1.54A | 16.87 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 127VAL A 142LEU A 122THR A 146ALA A 124 | 1.60A | 17.82 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 8 | MET B 61HIS B 94ILE B 23LEU B 88 | 1.75A | 16.87 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 8 | HIS B 94ILE B 23THR B 57LEU B 88 | 1.42A | 16.87 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 8 | MET A 61HIS A 94ILE A 23LEU A 88 | 1.73A | 16.87 | NoneNoneAMP A 201 ( 4.0A)None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 8 | LEU B 140ILE B 137LEU B 164LEU B 126 | 1.21A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 8 | ILE A 23LEU A 53THR A 57LEU A 88 | 1.62A | 16.87 | AMP A 201 ( 4.0A)NoneNoneNone | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | LEU C7072THR C7055ILE C7079ALA C6858ALA C6986 | 1.63A | 16.08 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 6 | GLN C6957ALA C6960THR C6918PHE C6954 | 1.49A | 16.84 | NoneNoneFMT C7113 ( 4.8A)None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 8 | LEU A6883ILE A6926LEU A6924LEU A6887 | 1.67A | 16.84 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 8 | HIS C6984LEU C7073ILE C7065LEU C7070 | 1.46A | 16.84 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 8 | MET C6863LEU C6852ILE C6926LEU C6857 | 1.67A | 16.84 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 8 | LEU C7073ILE C7069LEU C7070LEU C6961 | 1.55A | 16.84 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 8 | MET A6982LEU A6852LEU A6855THR A6989 | 1.79A | 16.84 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | LEU A6978THR A6970ILE A6969ALA A7002ALA A6966 | 1.65A | 16.08 | NoneFMT A7103 ( 3.0A)NoneNoneNone | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | LEU A6857LEU A6848THR A6854THR A6989ALA A6966 | 1.66A | 16.08 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 8 | MET A6863LEU A6852ILE A6926LEU A6857 | 1.66A | 16.84 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 8 | LEU C7072ILE C7069LEU C7078THR C7055 | 1.77A | 16.84 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 8 | LEU A7073ILE A7069LEU A7078THR A7055 | 1.77A | 16.84 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 8 | HIS C6867ILE C7005LEU C6852LEU C6924 | 1.31A | 16.84 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | LEU C7078ILE C7080ALA C6960ALA C7056THR C7055 | 1.44A | 16.08 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | LEU A7072THR A7055ILE A7079ALA A6858ALA A6986 | 1.63A | 16.08 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 8 | LEU A7073ILE A7065LEU A7070LEU A7010 | 1.57A | 16.84 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w75 | NSP10NSP16 (SARS-CoV-2) | 4 / 8 | LEU C7042GLN C6850LEU C6834LEU D4298 | 1.55A | 16.84 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 9 | LEU A7078ILE A7080ALA A6960ALA A7056THR A7055 | 1.42A | 16.08 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | LEU C6857LEU C6848THR C6854THR C6989ALA C6966 | 1.65A | 16.08 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | LEU C6978THR C6970ILE C6969ALA C7002ALA C6966 | 1.67A | 16.08 | NoneFMT C7107 ( 3.0A)NoneNoneNone | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 5 | LEU A6892ALA A6905THR A6908VAL C7092 | 1.63A | 15.97 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 8 | LEU C6883ILE C6926THR C6891LEU C6887 | 1.39A | 16.84 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 8 | LEU A7072ILE A7069LEU A7078THR A7055 | 1.73A | 16.84 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 8 | LEU A7073ILE A7065LEU A6961LEU A7078 | 1.78A | 16.84 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w75 | NSP10 (SARS-CoV-2) | 5 / 12 | LEU B4345THR B4309ILE B4308ALA B4307THR B4364 | 1.63A | 15.77 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 8 | HIS A6867ILE A7005LEU A6852LEU A6924 | 1.31A | 16.84 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 8 | LEU A6883ILE A6926THR A6891LEU A6887 | 1.44A | 16.84 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w75 | NSP10 (SARS-CoV-2) | 4 / 8 | LEU D4328ILE D4291THR D4364LEU D4365 | 1.63A | 16.38 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 6 | GLN C6850ALA C6802THR C6993PHE C6991 | 1.51A | 16.84 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | ILE A7080ALA A6960ALA A6858ALA A7056THR A7055 | 1.76A | 16.08 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 9 | LEU C7078ILE C7080ALA C6960ALA C7056THR C7055 | 1.43A | 16.08 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 8 | HIS A6984LEU A7073ILE A7065LEU A7070 | 1.49A | 16.84 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 6 | GLN A6850ALA A6802THR A6993PHE A6991 | 1.52A | 16.84 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | LEU A7078ILE A7080ALA A6960ALA A7056THR A7055 | 1.43A | 16.08 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 8 | LEU C6883ILE C6926LEU C6924LEU C6887 | 1.65A | 16.84 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 8 | LEU A7073ILE A7069LEU A7070LEU A7010 | 1.66A | 16.84 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 6 | GLN A6957ALA A6960THR A6918PHE A6954 | 1.48A | 16.84 | NoneNoneFMT A7109 ( 4.5A)None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 5 | LEU C6892ALA C6905THR C6908VAL A7092 | 1.61A | 15.97 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 5 | LEU A6892ALA A6905THR A6908VAL C7092 | 1.62A | 15.97 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 5 | LEU C6892ALA C6905THR C6908VAL A7092 | 1.61A | 15.97 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w75 | NSP10 (SARS-CoV-2) | 5 / 12 | LEU D4345THR D4309ILE D4308ALA D4307THR D4364 | 1.62A | 15.77 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 8 | LEU C7073ILE C7065LEU C6961LEU C7078 | 1.75A | 16.84 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 8 | LEU A7073ILE A7069LEU A7070LEU A6961 | 1.54A | 16.84 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w75 | NSP10 (SARS-CoV-2) | 4 / 8 | LEU B4328ILE B4291THR B4364LEU B4365 | 1.48A | 16.38 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | LEU B 113THR B 90ALA B 145ALA B 139THR B 102 | 1.48A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | LEU B 118THR B 277ILE B 276ALA B 261GLU B 263 | 1.58A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 4 / 5 | LEU B 211ALA B 261THR B 119ILE B 123 | 1.44A | 18.47 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 4 / 6 | GLN C 122ALA C 114ALA C 116PHE C 304 | 1.40A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 4 / 6 | HIS B 272ALA B 114ALA B 116THR B 168 | 1.72A | None CL B 502 ( 3.8A)NoneNone | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | LEU C 113THR C 90ALA C 145ALA C 139THR C 102 | 1.44A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 4 / 5 | LEU A 211ALA A 261THR A 119ILE A 123 | 1.50A | 18.47 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | LEU C 152LEU C 132THR C 168ALA C 116ALA C 144 | 1.57A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 4 / 6 | GLN A 122ALA A 114ALA A 116PHE A 304 | 1.43A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 4 / 6 | GLN B 122ALA B 114ALA B 116PHE B 304 | 1.46A | None CL B 502 ( 3.8A)NoneNone | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 4 / 5 | LEU A 211ALA A 261THR A 119ILE A 123 | 1.46A | 18.47 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 118THR A 277ILE A 276ALA A 261GLU A 263 | 1.52A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | LEU C 117ILE C 151ALA C 149THR C 90ALA C 144 | 1.48A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 117ILE A 151ALA A 149THR A 90ALA A 144 | 1.46A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | LEU C 117ILE C 151ALA C 149THR C 90ALA C 139 | 1.46A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 4 / 5 | LEU B 211ALA B 261THR B 119ILE B 123 | 1.47A | 18.47 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | LEU B 117ILE B 151ALA B 149THR B 90ALA B 144 | 1.47A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 117ILE A 151ALA A 149THR A 90ALA A 139 | 1.43A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w9q | 3C-LIKE PROTEINASEPEPTIDE, NSP9 FUSION (SARS-CoV-2) | 4 / 6 | GLN A 20ALA A 15ALA A 54THR A 67 | 1.42A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6w9q | 3C-LIKE PROTEINASEPEPTIDE, NSP9 FUSION (SARS-CoV-2) | 6 / 12 | LEU A 69LEU A 48ALA A 22THR A 24ALA A 15ALA A 28 | 1.68A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6w9q | 3C-LIKE PROTEINASEPEPTIDE, NSP9 FUSION (SARS-CoV-2) | 4 / 6 | GLN A 20ALA A 16ALA A 54THR A 67 | 1.52A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wcf | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 127VAL A 142LEU A 122THR A 146ALA A 124 | 1.57A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wcf | NSP3 (SARS-CoV-2) | 5 / 9 | LEU A 12PHE A 168VAL A 144LEU A 160ILE A 137 | 1.73A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wcf | NSP3 (SARS-CoV-2) | 4 / 8 | LEU A 140ILE A 137LEU A 164LEU A 126 | 1.24A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wen | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 127VAL A 142LEU A 122THR A 146ALA A 124 | 1.58A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wen | NSP3 (SARS-CoV-2) | 4 / 8 | LEU A 140ILE A 137LEU A 164LEU A 126 | 1.30A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wey | NSP3 (SARS-CoV-2) | 4 / 8 | LEU A 344ILE A 341LEU A 368LEU A 330 | 1.20A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wey | NSP3 (SARS-CoV-2) | 5 / 12 | LEU A 331VAL A 346LEU A 326THR A 350ALA A 328 | 1.59A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6wiq | NSP7NSP8 (SARS-CoV-2) | 4 / 5 | LEU A 60THR B 137VAL B 131ILE B 132 | 1.72A | 12.98 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wiq | NSP7NSP8 (SARS-CoV-2) | 4 / 8 | LEU B 103ILE B 106LEU A 56LEU B 95 | 1.18A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wiq | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | VAL A 6ALA A 48GLU A 50THR A 46ALA B 102 | 1.29A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wiq | NSP7NSP8 (SARS-CoV-2) | 4 / 8 | LEU B 95ILE B 107LEU A 56LEU B 91 | 1.04A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6wiq | NSP8 (SARS-CoV-2) | 4 / 5 | LEU B 180ALA B 162VAL B 186ILE B 185 | 1.62A | 15.82 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6wiq | NSP8 (SARS-CoV-2) | 4 / 5 | LEU B 180ALA B 162VAL B 186ILE B 185 | 1.64A | 15.82 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wiq | NSP7NSP8 (SARS-CoV-2) | 5 / 8 | MET B 90LEU B 103ILE B 107THR A 9LEU B 98 | 1.69A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 4 / 6 | GLN B 272ALA C 311ALA B 267THR B 265 | 1.59A | None CL D 401 ( 4.1A) CL D 401 ( 4.2A)None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 8 | LEU D 339GLN D 306ILE D 337LEU C 331LEU D 353 | 1.74A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 8 | LEU A 339GLN A 306ILE A 337LEU B 331LEU A 353 | 1.76A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 4 / 8 | LEU D 331GLN D 260LEU C 353LEU C 339 | 1.03A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 4 / 6 | ALA D 308ALA C 311THR D 263PHE D 274 | 1.49A | None CL D 401 ( 4.1A)NoneNone | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 4 / 8 | LEU A 331GLN A 260LEU B 353LEU B 339 | 1.09A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 4 / 8 | LEU E 331GLN E 260LEU F 353LEU F 339 | 1.17A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 4 / 6 | GLN B 272ALA D 305ALA B 267THR B 265 | 1.55A | None CL D 401 ( 4.6A) CL D 401 ( 4.2A)None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 8 | LEU F 339GLN F 306ILE F 337LEU E 331LEU F 353 | 1.73A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 4 / 8 | LEU C 331GLN C 260LEU D 353LEU D 339 | 1.06A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 4 / 6 | ALA C 308ALA D 311THR C 263PHE C 274 | 1.50A | None CL C 401 ( 3.8A)NoneNone | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 4 / 6 | HIS D 300GLN B 272ALA B 267THR B 265 | 1.65A | NoneNone CL D 401 ( 4.2A)None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 8 | LEU B 339GLN B 306ILE B 337LEU A 331LEU B 353 | 1.75A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 4 / 6 | ALA F 308ALA E 311THR F 263PHE F 274 | 1.48A | None CL F 401 ( 3.7A)NoneNone | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 8 | LEU C 339GLN C 306ILE C 337LEU D 331LEU C 353 | 1.73A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 4 / 6 | GLN D 303ALA C 311ALA B 267THR B 265 | 1.73A | None CL D 401 ( 4.1A) CL D 401 ( 4.2A)None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 4 / 6 | ALA E 308ALA F 311THR E 263PHE E 274 | 1.50A | None CL E 401 ( 4.0A)NoneNone | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 4 / 6 | ALA A 308ALA B 311THR A 263PHE A 274 | 1.48A | None CL A 401 ( 3.7A)NoneNone | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 4 / 8 | LEU B 331GLN B 260LEU A 353LEU A 339 | 1.10A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 8 | LEU E 339GLN E 306ILE E 337LEU F 331LEU E 353 | 1.75A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 4 / 8 | LEU F 331GLN F 260LEU E 353LEU E 339 | 1.06A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 4 / 6 | GLN F 294ALA F 273ALA F 264THR F 296 | 1.73A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wji | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 4 / 6 | ALA B 308ALA A 311THR B 263PHE B 274 | 1.43A | None CL B 401 ( 3.7A)NoneNone | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | LEU C7078ILE C7080ALA C6960ALA C7056THR C7055 | 1.45A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 8 | HIS A6867ILE A7005LEU A6852LEU A6924 | 1.32A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 5 | LEU A6892ALA A6905THR A6908VAL C7092 | 1.59A | 22.41 | NoneNoneNoneFMT C7107 ( 4.8A) | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 9 | LEU A7078ILE A7080ALA A6960ALA A7056THR A7055 | 1.43A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 5 | LEU A6892ALA A6905THR A6908VAL C7092 | 1.56A | 22.41 | NoneNoneNoneFMT C7107 ( 4.8A) | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 9 | LEU C7078ILE C7080ALA C6960ALA C7056THR C7055 | 1.44A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 6 | GLN A6850ALA A6802THR A6993PHE A6991 | 1.51A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 8 | HIS C6867ILE C7005LEU C6852LEU C6924 | 1.33A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | LEU A7078ILE A7080ALA A6960ALA A7056THR A7055 | 1.44A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 5 | LEU C6892ALA C6905THR C6908VAL A7092 | 1.71A | 22.41 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 5 | LEU C6892ALA C6905THR C6908VAL A7092 | 1.68A | 22.41 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 6 | GLN A6957ALA A6960THR A6918PHE A6954 | 1.47A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 6 | GLN C6850ALA C6802THR C6993PHE C6991 | 1.51A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | THR D 54ILE D 157ALA D 156ALA C 152ALA C 156 | 1.30A | NoneNoneNoneNoneMES D 201 ( 4.8A) | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 9 | LEU A 113LEU A 121ILE A 130GLU A 118ALA A 119 | 1.80A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wkp | NUCLEOCAPSID PROTEIN (SARS-CoV-2) | 5 / 12 | THR D 54ILE D 157ALA D 156ALA C 152ALA C 155 | 1.44A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wkq | NSP16 (SARS-CoV-2) | 4 / 6 | GLN C6957ALA C6960THR C6918PHE C6954 | 1.49A | NoneNoneFMT C7108 ( 4.9A)None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6wkq | NSP16 (SARS-CoV-2) | 4 / 5 | LEU C6892ALA C6905THR C6908VAL A7092 | 1.70A | 22.41 | NoneNoneNone NA A7102 ( 4.8A) | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6wkq | NSP16 (SARS-CoV-2) | 4 / 5 | LEU A6892ALA A6905THR A6908VAL C7092 | 1.69A | 22.41 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | LEU A7078ILE A7080ALA A6960ALA A7056THR A7055 | 1.43A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wkq | NSP16 (SARS-CoV-2) | 4 / 6 | GLN A6957ALA A6960THR A6918PHE A6954 | 1.45A | NoneNoneFMT A7108 ( 4.8A)None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 9 | LEU A7078ILE A7080ALA A6960ALA A7056THR A7055 | 1.42A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 9 | LEU C7078ILE C7080ALA C6960ALA C7056THR C7055 | 1.43A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wkq | NSP16 (SARS-CoV-2) | 4 / 8 | HIS C6867ILE C7005LEU C6852LEU C6924 | 1.32A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | LEU C7078ILE C7080ALA C6960ALA C7056THR C7055 | 1.44A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wkq | NSP16 (SARS-CoV-2) | 4 / 6 | GLN C6850ALA C6802THR C6993PHE C6991 | 1.51A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wkq | NSP16 (SARS-CoV-2) | 4 / 6 | GLN A6850ALA A6802THR A6993PHE A6991 | 1.51A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wkq | NSP16 (SARS-CoV-2) | 4 / 8 | HIS A6867ILE A7005LEU A6852LEU A6924 | 1.33A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 4 / 5 | LEU B 251THR B 275VAL B 321ILE B 328 | 1.58A | 22.07 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 4 / 5 | LEU A 251THR A 275VAL A 321ILE A 328 | 1.36A | 22.07 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 4 / 5 | LEU A 251THR A 275VAL A 321ILE A 328 | 1.50A | 22.07 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 4 / 5 | LEU B 251THR B 275VAL B 321ILE B 328 | 1.44A | 22.07 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 4 / 5 | LEU B 143ALA B 138VAL B 78ILE B 80 | 1.66A | 22.07 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 5 / 9 | LEU A 332PHE A 342VAL A 339ILE A 306GLU A 305 | 1.71A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 5 | LEU A 250ALA A 255VAL A 212ILE A 213 | 1.64A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 5 | LEU A 205THR A 257VAL A 212ILE A 213 | 1.70A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 9 | LEU A 89PHE A 66VAL A 20LEU A 58ILE A 43 | 1.50A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 5 | LEU A 271ALA A 266VAL A 212ILE A 259 | 1.49A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 5 | ALA A 210THR A 257VAL A 261ILE A 259 | 1.38A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 8 | LEU A 208ILE A 281LEU A 287LEU A 268 | 1.27A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 205ILE A 259ALA A 260ALA A 266THR A 224 | 1.52A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 89PHE A 66VAL A 20LEU A 58ILE A 43 | 1.49A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 9 | LEU A 205ILE A 259ALA A 260ALA A 266THR A 224 | 1.53A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 5 | LEU A 271ALA A 266VAL A 212ILE A 259 | 1.59A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 8 | LEU B 140ILE B 137LEU B 164LEU B 126 | 1.26A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 8 | LEU C 140ILE C 137LEU C 164LEU C 126 | 1.25A | NoneNoneNoneAPR C 201 (-4.9A) | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 8 | LEU A 140ILE A 137LEU A 164LEU A 126 | 1.24A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 8 | LEU D 140ILE D 137LEU D 164LEU D 126 | 1.25A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 5 | LEU C 127ALA C 154VAL C 16ILE C 18 | 1.60A | 16.63 | NoneAPR C 201 (-4.5A)NoneNone | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wq3 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 8 | HIS A6867ILE A7005LEU A6852LEU A6924 | 1.31A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wq3 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | LEU A7072THR A7055ILE A7079ALA A6858ALA A6986 | 1.59A | NoneNoneNoneNone8NK A7103 ( 3.8A) | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wq3 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | LEU A7078ILE A7080ALA A6960ALA A7056THR A7055 | 1.45A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wq3 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 6 | GLN A6957ALA A6960THR A6918PHE A6954 | 1.48A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wq3 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 9 | LEU A7078ILE A7080ALA A6960ALA A7056THR A7055 | 1.44A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wq3 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 6 | GLN A6850ALA A6802THR A6993PHE A6991 | 1.51A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6wqd | NSP8 (SARS-CoV-2) | 4 / 5 | LEU D 180ALA D 162VAL D 186ILE D 185 | 1.53A | 15.82 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 4 / 5 | LEU C 60THR D 137VAL D 131ILE D 132 | 1.62A | 12.98 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | VAL A 6LEU B 122ALA A 48GLU A 50THR A 46 | 1.55A | NoneNoneNoneEDO B 302 ( 4.2A)None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 5 / 9 | LEU D 103VAL C 6LEU D 122ALA C 48GLU C 50 | 1.77A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6wqd | NSP8 (SARS-CoV-2) | 4 / 5 | LEU B 180ALA B 162VAL B 186ILE B 185 | 1.58A | 15.82 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 5 / 8 | MET D 90LEU D 103ILE D 107THR C 9LEU D 98 | 1.68A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 4 / 8 | LEU D 103ILE D 106LEU C 56LEU D 95 | 1.25A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 5 / 8 | MET A 62LEU B 95ILE B 107LEU A 56LEU B 91 | 1.57A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 5 / 8 | LEU A 56ILE B 106LEU B 103THR A 9LEU A 13 | 1.74A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | VAL C 6ALA C 48GLU C 50THR C 46ALA D 102 | 1.38A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6wqd | NSP8 (SARS-CoV-2) | 4 / 5 | LEU D 180ALA D 162VAL D 186ILE D 185 | 1.56A | 15.82 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 5 / 9 | LEU D 91PHE D 92VAL C 66LEU D 103ILE D 107 | 1.60A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 5 / 8 | MET B 90LEU B 103ILE B 107THR A 9LEU B 98 | 1.64A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6wqd | NSP8 (SARS-CoV-2) | 4 / 5 | LEU B 180ALA B 162VAL B 186ILE B 185 | 1.54A | 15.82 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 5 / 8 | LEU C 56ILE D 106LEU D 103THR C 9LEU C 13 | 1.75A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 4 / 5 | LEU A 60THR B 137VAL B 131ILE B 132 | 1.58A | 12.98 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wqd | NSP8 (SARS-CoV-2) | 5 / 12 | THR B 187ILE B 156ALA B 188ALA B 152THR B 148 | 1.53A | NoneNoneNoneEDO B 302 ( 4.3A)None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 5 / 9 | LEU B 91PHE B 92VAL A 66LEU B 103ILE B 107 | 1.58A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 5 / 8 | MET C 62LEU D 95ILE D 107LEU C 56LEU D 91 | 1.57A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 4 / 8 | LEU B 103ILE B 106LEU A 56LEU B 95 | 1.23A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 4 / 5 | LEU A 71THR B 137VAL B 131ILE B 132 | 1.66A | 12.98 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | VAL A 6ALA A 48GLU A 50THR A 46ALA B 102 | 1.25A | NoneNoneEDO B 302 ( 4.2A)NoneEDO B 302 ( 4.2A) | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | LEU B 91PHE B 92VAL A 66LEU B 103ILE B 107 | 1.58A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 5 / 12 | VAL C 6LEU D 122ALA C 48GLU C 50THR C 46 | 1.53A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wqd | NSP8 (SARS-CoV-2) | 5 / 12 | THR D 187ILE D 156ALA D 188ALA D 152THR D 148 | 1.54A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 89PHE A 66VAL A 20LEU A 58ILE A 43 | 1.42A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 5 | LEU A 250ALA A 255VAL A 212ILE A 213 | 1.64A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 8 | LEU A 208ILE A 281LEU A 287LEU A 268 | 1.23A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 5 | LEU A 271ALA A 266VAL A 212ILE A 259 | 1.50A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 9 | LEU A 89PHE A 66VAL A 20LEU A 58ILE A 43 | 1.43A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 5 | LEU A 205THR A 257VAL A 212ILE A 213 | 1.64A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 5 | LEU A 271ALA A 266VAL A 212ILE A 259 | 1.61A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 5 | ALA A 210THR A 257VAL A 261ILE A 259 | 1.44A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 205ILE A 259ALA A 260ALA A 266THR A 224 | 1.50A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 9 | LEU A 205ILE A 259ALA A 260ALA A 266THR A 224 | 1.51A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wrh | PEPTIDASE C16 (SARS-CoV-2) | 5 / 9 | LEU A 234PHE A 216VAL A 220LEU A 199THR A 197 | 1.62A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6wrh | PEPTIDASE C16 (SARS-CoV-2) | 4 / 5 | LEU A 211ALA A 261THR A 115VAL A 165 | 1.66A | 20.45 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6wrh | PEPTIDASE C16 (SARS-CoV-2) | 4 / 5 | LEU A 211ALA A 261THR A 119ILE A 123 | 1.52A | 20.45 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6wrh | PEPTIDASE C16 (SARS-CoV-2) | 4 / 5 | LEU A 211ALA A 261THR A 119ILE A 123 | 1.50A | 20.45 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wrh | PEPTIDASE C16 (SARS-CoV-2) | 4 / 8 | LEU A 172ILE A 151THR A 119LEU A 120 | 1.23A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wrh | PEPTIDASE C16 (SARS-CoV-2) | 5 / 12 | LEU A 117ILE A 151ALA A 149THR A 90ALA A 144 | 1.58A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6wrh | PEPTIDASE C16 (SARS-CoV-2) | 5 / 12 | LEU A 117ILE A 151ALA A 149THR A 90ALA A 139 | 1.40A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6wrh | PEPTIDASE C16 (SARS-CoV-2) | 4 / 6 | GLN A 122ALA A 114ALA A 116PHE A 304 | 1.50A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 5 | ALA A 210THR A 257VAL A 261ILE A 259 | 1.41A | 20.35 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 8 | GLN A 244ILE A 249THR A 201LEU A 242 | 1.76A | 16.38 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 9 | LEU A 89PHE A 66VAL A 20LEU A 58ILE A 43 | 1.50A | 15.60 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 8 | LEU A 227GLN A 244LEU A 242LEU A 262 | 1.50A | 16.38 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 8 | LEU A 208ILE A 281LEU A 287LEU A 268 | 1.27A | 16.38 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU A 205ILE A 259ALA A 260ALA A 266THR A 224 | 1.49A | 15.60 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 5 | LEU A 271ALA A 266VAL A 212ILE A 259 | 1.46A | 20.35 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 8 | LEU A 250ILE A 249THR A 201LEU A 205 | 1.62A | 16.38 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 5 | LEU A 250ALA A 255VAL A 212ILE A 213 | 1.60A | 20.35 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | PHE A 219LEU A 282ILE A 281ALA A 206ALA A 210 | 1.75A | 15.60 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 8 | MET A 162HIS A 164ILE A 43LEU A 27 | 1.56A | 16.38 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU A 89PHE A 66VAL A 20LEU A 58ILE A 43 | 1.49A | 15.60 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 5 | LEU A 271ALA A 266VAL A 212ILE A 259 | 1.57A | 20.35 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 5 | LEU A 250ALA A 255VAL A 212ILE A 213 | 1.80A | 20.35 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 8 | LEU A 208LEU A 268THR A 201LEU A 205 | 1.63A | 16.38 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 9 | LEU A 205ILE A 259ALA A 260ALA A 266THR A 224 | 1.50A | 15.60 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 8 | MET A 165HIS A 164LEU A 57ILE A 43 | 1.42A | 16.38 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 8 | MET A 165HIS A 41LEU A 50THR A 190 | 1.77A | 16.38 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 5 | LEU A 271ALA A 266THR A 225VAL A 233 | 1.79A | 20.35 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 5 | LEU A 205THR A 257VAL A 212ILE A 213 | 1.64A | 20.35 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 8 | MET A 276LEU A 205LEU A 268LEU A 208 | 1.66A | 16.38 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 8 | LEU A 227GLN A 244THR A 225LEU A 262 | 1.55A | 16.38 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 5 | LEU B 180ALA B 162VAL B 186ILE B 185 | 1.53A | 14.15 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 12 | VAL A 6ALA A 48GLU A 50THR A 46ALA B 102 | 1.46A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 8 | MET B 90LEU B 103ILE B 107THR A 9LEU B 98 | 1.70A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 8 | LEU C 56ILE D 106LEU D 103THR C 9LEU C 13 | 1.69A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 12 | VAL C 6ALA C 48GLU C 50THR C 46ALA D 102 | 1.34A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 12 | VAL C 6LEU D 122ALA C 48GLU C 50THR C 46 | 1.51A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 5 | LEU D 180ALA D 162VAL D 186ILE D 185 | 1.54A | 14.15 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 12 | THR B 187ILE B 156ALA B 188ALA B 152THR B 148 | 1.52A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 5 | LEU A 60THR B 137VAL B 131ILE B 132 | 1.63A | 11.55 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 5 | LEU C 60THR D 137VAL D 131ILE D 132 | 1.62A | 11.55 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 8 | LEU B 103ILE B 106LEU A 56LEU B 95 | 1.21A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 8 | MET A 62LEU B 95ILE B 107LEU A 56LEU B 91 | 1.62A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 8 | MET D 90LEU D 103ILE D 107THR C 9LEU D 98 | 1.70A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 8 | MET C 62LEU D 95ILE D 107LEU C 56LEU D 91 | 1.63A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 5 | LEU C 60THR D 137VAL D 131ILE D 132 | 1.61A | 11.55 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 12 | THR D 187ILE D 156ALA D 188ALA D 152THR D 148 | 1.48A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 9 | LEU D 103VAL C 6LEU D 122ALA C 48GLU C 50 | 1.79A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 5 | LEU B 180ALA B 162VAL B 186ILE B 185 | 1.50A | 14.15 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 8 | LEU A 56ILE B 106LEU B 103THR A 9LEU A 13 | 1.69A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 5 | LEU D 180ALA D 162VAL D 186ILE D 185 | 1.51A | 14.15 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 8 | LEU D 103ILE D 106LEU C 56LEU D 95 | 1.21A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6yi3 | NUCLEOPROTEIN (SARS-CoV-2) | 4 / 8 | LEU A 121GLN A 30LEU A 119LEU A 127 | 1.32A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 9 | PHE A 400VAL A 433ILE A 402GLU A 406ALA A 419 | 1.75A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 5 | LEU E 425THR E 376VAL E 510ILE E 434 | 1.37A | 18.18 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 9 | LEU E 368PHE E 338VAL E 511ILE E 358ALA E 397 | 1.69A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 9 | PHE E 400VAL E 433ILE E 402GLU E 406ALA E 419 | 1.73A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | VAL A 407LEU A 513THR A 376ILE A 434ALA A 435 | 1.18A | DMS A 903 ( 4.7A)NoneNoneNoneNone | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | PHE E 400VAL E 512ILE E 402ALA E 411ALA E 419 | 1.56A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 5 | LEU A 425THR A 376VAL A 510ILE A 434 | 1.36A | 18.18 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 5 | LEU A 425ALA A 419VAL A 510ILE A 402 | 1.53A | 18.18 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 9 | LEU A 368PHE A 338VAL A 511ILE A 358ALA A 397 | 1.70A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | VAL E 407LEU E 513THR E 376ILE E 434ALA E 435 | 1.18A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 5 | LEU A 425ALA A 419VAL A 510ILE A 402 | 1.68A | 18.18 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | PHE A 400VAL A 512ILE A 402ALA A 411ALA A 419 | 1.54A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6yla | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 5 | LEU E 425ALA E 419VAL E 510ILE E 402 | 1.58A | 18.18 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6ym0 | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 5 | LEU E 425ALA E 419VAL E 510ILE E 402 | 1.59A | 18.18 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6ym0 | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 9 | LEU E 368PHE E 338VAL E 511ILE E 358ALA E 397 | 1.72A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6ym0 | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 9 | PHE E 400VAL E 433ILE E 402GLU E 406ALA E 419 | 1.70A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6ym0 | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | VAL E 407LEU E 513THR E 376ILE E 434ALA E 435 | 1.17A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6ym0 | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 5 | LEU E 425THR E 376VAL E 510ILE E 434 | 1.34A | 18.18 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 8 | LEU A 208ILE A 281LEU A 287LEU A 268 | 1.24A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU A 89PHE A 66VAL A 20LEU A 58ILE A 43 | 1.47A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 5 | LEU A 271ALA A 266VAL A 212ILE A 259 | 1.55A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 5 | ALA A 210THR A 257VAL A 261ILE A 259 | 1.34A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU A 205ILE A 259ALA A 260ALA A 266THR A 224 | 1.54A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 5 | LEU A 271ALA A 266VAL A 212ILE A 259 | 1.46A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 9 | LEU A 89PHE A 66VAL A 20LEU A 58ILE A 43 | 1.48A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 5 | LEU A 205THR A 257VAL A 212ILE A 213 | 1.70A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 5 | LEU A 250ALA A 255VAL A 212ILE A 213 | 1.60A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 9 | LEU A 205ILE A 259ALA A 260ALA A 266THR A 224 | 1.55A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 5 | LEU E 425THR E 376VAL E 510ILE E 434 | 1.36A | 17.69 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | PHE E 400VAL E 512ILE E 402ALA E 411ALA E 419 | 1.57A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | PHE A 400VAL A 512ILE A 402ALA A 411ALA A 419 | 1.55A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 5 | LEU A 425THR A 376VAL A 510ILE A 434 | 1.36A | 17.69 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 5 | LEU E 425ALA E 419VAL E 510ILE E 402 | 1.58A | 17.69 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 9 | LEU E 368PHE E 338VAL E 511ILE E 358ALA E 397 | 1.69A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | VAL A 407LEU A 513THR A 376ILE A 434ALA A 435 | 1.18A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 9 | PHE E 400VAL E 433ILE E 402GLU E 406ALA E 419 | 1.73A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 4 / 5 | LEU A 425ALA A 419VAL A 510ILE A 402 | 1.58A | 17.69 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 9 | LEU A 368PHE A 338VAL A 511ILE A 358ALA A 397 | 1.69A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | VAL E 407LEU E 513THR E 376ILE E 434ALA E 435 | 1.17A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6yor | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 9 | PHE A 400VAL A 433ILE A 402GLU A 406ALA A 419 | 1.72A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 5 | LEU A 250ALA A 255VAL A 212ILE A 213 | 1.61A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 5 | ALA A 210THR A 257VAL A 261ILE A 259 | 1.39A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 5 | LEU A 271ALA A 266VAL A 212ILE A 259 | 1.57A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 8 | LEU A 208ILE A 281LEU A 287LEU A 268 | 1.25A | NoneNonePEG A 404 (-2.9A)None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 9 | LEU A 205ILE A 259ALA A 260ALA A 266THR A 224 | 1.46A | NoneNoneNoneNoneIMD A 402 (-3.1A) | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 5 | LEU A 205THR A 257VAL A 212ILE A 213 | 1.56A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 9 | LEU A 89PHE A 66VAL A 20LEU A 58ILE A 43 | 1.52A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU A 89PHE A 66VAL A 20LEU A 58ILE A 43 | 1.51A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU A 205ILE A 259ALA A 260ALA A 266THR A 224 | 1.44A | NoneNoneNoneNoneIMD A 402 (-3.1A) | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 5 | LEU A 271ALA A 266VAL A 212ILE A 259 | 1.47A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 4 / 8 | LEU B 140ILE B 137LEU B 164LEU B 126 | 1.25A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU E 127VAL E 142LEU E 122THR E 146ALA E 124 | 1.57A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 4 / 8 | LEU A 140ILE A 137LEU A 164LEU A 126 | 1.22A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 4 / 8 | LEU C 140ILE C 137LEU C 164LEU C 126 | 1.24A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 4 / 8 | LEU E 140ILE E 137LEU E 164LEU E 126 | 1.20A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 4 / 8 | LEU D 140ILE D 137LEU D 164LEU D 126 | 1.28A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 9 | PHE E 132VAL E 41LEU E 127ALA E 39ALA E 112 | 1.79A | EPE E 202 (-3.2A)NoneNoneNoneNone | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | LEU E 127VAL E 142LEU E 122THR E 146ALA E 124 | 1.59A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 4 / 8 | LEU D 140ILE D 137LEU D 164LEU D 126 | 1.25A | NoneNoneNoneAPR D 201 (-4.5A) | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 4 / 8 | LEU E 140ILE E 137LEU E 164LEU E 126 | 1.21A | NoneNoneNoneAPR E 201 (-4.7A) | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 4 / 8 | LEU B 140ILE B 137LEU B 164LEU B 126 | 1.23A | NoneNoneNoneAPR B 201 (-4.7A) | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 4 / 8 | LEU A 140ILE A 137LEU A 164LEU A 126 | 1.19A | NoneNoneNoneAPR A 201 (-4.8A) | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 4 / 8 | LEU C 140ILE C 137LEU C 164LEU C 126 | 1.19A | NoneNoneNoneAPR C 201 (-4.8A) | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 4 / 8 | LEU C 140ILE C 137LEU C 164LEU C 126 | 1.24A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 4 / 8 | LEU B 140ILE B 137LEU B 164LEU B 126 | 1.23A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 4 / 8 | LEU A 140ILE A 137LEU A 164LEU A 126 | 1.17A | NoneEDO A 206 (-4.6A)NoneNone | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6zsl | SARS-COV-2 HELICASENSP13 (SARS-CoV-2) | 4 / 5 | LEU B 581ALA B 564THR B 566ILE B 448 | 1.12A | 20.79 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 6zsl | SARS-COV-2 HELICASENSP13 (SARS-CoV-2) | 4 / 5 | LEU A 581ALA A 564THR A 566ILE A 448 | 1.08A | 20.79 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 4 / 5 | LEU A 271ALA A 266VAL A 212ILE A 259 | 1.45A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 4 / 5 | ALA A 210THR A 257VAL A 261ILE A 259 | 1.38A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 89PHE A 66VAL A 20LEU A 58ILE A 43 | 1.47A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 4 / 5 | LEU A 205THR A 257VAL A 212ILE A 213 | 1.70A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 205ILE A 259ALA A 260ALA A 266THR A 224 | 1.53A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 4 / 8 | LEU A 208ILE A 281LEU A 287LEU A 268 | 1.28A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 5 / 9 | LEU A 89PHE A 66VAL A 20LEU A 58ILE A 43 | 1.48A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 5 / 9 | LEU A 205ILE A 259ALA A 260ALA A 266THR A 224 | 1.54A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 4 / 5 | LEU A 250ALA A 255VAL A 212ILE A 213 | 1.64A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 4 / 5 | LEU A 271ALA A 266VAL A 212ILE A 259 | 1.55A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 7btf | NSP12 (SARS-CoV-2) | 4 / 6 | GLN A 773ALA A 777ALA A 706THR A 710 | 1.67A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 7btf | NSP8 (SARS-CoV-2) | 5 / 5 | LEU B 98ALA B 125THR B 123VAL B 115ILE B 119 | 1.59A | 19.75 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7btf | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 575ALA A 690VAL A 476ILE A 696 | 1.68A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7btf | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 245ALA A 185THR A 189VAL A 234 | 1.57A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 7btf | NSP7NSP8 (SARS-CoV-2) | 4 / 8 | LEU D 103ILE D 107THR C 9LEU D 98 | 1.32A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7btf | NSP8 (SARS-CoV-2) | 5 / 5 | LEU B 98ALA B 125THR B 123VAL B 115ILE B 119 | 1.53A | 19.75 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 7btf | NSP7NSP8 (SARS-CoV-2) | 4 / 8 | LEU D 95ILE D 107LEU C 56LEU D 91 | 1.00A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 7btf | NSP12 (SARS-CoV-2) | 4 / 8 | HIS A 133LEU A 727GLN A 724LEU A 731 | 1.32A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 7btf | NSP8 (SARS-CoV-2) | 5 / 9 | LEU D 169VAL D 186ALA D 188GLU D 155THR D 146 | 1.42A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | THR A 586ALA A 585THR A 582ALA A 580THR A 591 | 1.54A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7btf | NSP12NSP8 (SARS-CoV-2) | 4 / 5 | LEU A 387ALA B 188VAL B 131ILE B 185 | 1.43A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 7btf | NSP8 (SARS-CoV-2) | 5 / 12 | THR D 187ILE D 156ALA D 188ALA D 152THR D 148 | 1.51A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7btf | NSP12 (SARS-CoV-2) | 4 / 5 | ALA A 529THR A 531VAL A 373ILE A 536 | 1.67A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 7btf | NSP8 (SARS-CoV-2) | 4 / 5 | ALA B 102THR B 123VAL B 115ILE B 120 | 1.46A | 19.75 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 7btf | NSP7NSP8 (SARS-CoV-2) | 4 / 5 | LEU C 60THR D 137VAL D 131ILE D 132 | 1.58A | 13.10 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 7btf | NSP8 (SARS-CoV-2) | 5 / 12 | VAL D 130ILE D 156ALA D 188GLU D 155ALA D 152 | 1.57A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 7btf | NSP12 (SARS-CoV-2) | 4 / 8 | LEU A 575LEU A 638THR A 686LEU A 576 | 0.92A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7btf | NSP8 (SARS-CoV-2) | 4 / 5 | LEU B 180ALA B 162VAL B 186ILE B 185 | 1.59A | 19.75 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 7btf | NSP12 (SARS-CoV-2) | 4 / 5 | ALA A 250THR A 248VAL A 128ILE A 244 | 1.54A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7btf | NSP12NSP8 (SARS-CoV-2) | 4 / 5 | LEU A 387THR B 141VAL B 131ILE B 132 | 1.72A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 187LEU A 282ALA A 253THR A 252ALA A 250 | 1.55A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 673THR A 538ILE A 539ALA A 376ALA A 382 | 1.35A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 7btf | NSP8 (SARS-CoV-2) | 4 / 5 | LEU D 180ALA D 162VAL D 186ILE D 185 | 1.55A | 19.75 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 7btf | NSP8 (SARS-CoV-2) | 5 / 9 | LEU B 169VAL B 186ALA B 188GLU B 155THR B 146 | 1.72A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7btf | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 186ALA A 250THR A 248VAL A 128 | 1.66A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 7btf | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 146ALA A 130VAL A 182ILE A 244 | 1.49A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 883LEU A 891ILE A 888ALA A 863ALA A 840 | 1.57A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 7btf | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 245ALA A 185THR A 189VAL A 234 | 1.61A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 7btf | NSP12 (SARS-CoV-2) | 4 / 8 | LEU A 245ILE A 244LEU A 241LEU A 186 | 1.13A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 7btf | NSP8 (SARS-CoV-2) | 4 / 5 | LEU B 180ALA B 162VAL B 186ILE B 185 | 1.65A | 19.75 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 7btf | NSP7NSP8 (SARS-CoV-2) | 4 / 8 | LEU D 103ILE D 106LEU C 56LEU D 95 | 1.23A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 7btf | NSP12NSP8 (SARS-CoV-2) | 4 / 5 | LEU A 387ALA B 188VAL B 131ILE B 185 | 1.30A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 7btf | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | LEU A 372PHE A 368LEU A 514THR B 84ALA B 86 | 1.57A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7btf | NSP7NSP8 (SARS-CoV-2) | 4 / 5 | LEU C 60THR D 137VAL D 131ILE D 132 | 1.61A | 13.10 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7btf | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 329ALA A 379VAL A 359ILE A 333 | 1.46A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 7btf | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 575ALA A 690VAL A 476ILE A 696 | 1.56A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7btf | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 146ALA A 130VAL A 182ILE A 244 | 1.60A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 7btf | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | LEU B 117VAL A 398ILE B 119ALA B 125THR B 124 | 1.58A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 7btf | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 329ALA A 379VAL A 359ILE A 333 | 1.37A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7btf | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 576ALA A 690VAL A 587ILE A 757 | 1.64A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7btf | NSP8 (SARS-CoV-2) | 4 / 5 | LEU D 180ALA D 162VAL D 186ILE D 185 | 1.49A | 19.75 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 7btf | NSP12NSP8 (SARS-CoV-2) | 5 / 9 | LEU B 117LEU A 673ILE A 539ALA A 376ALA A 382 | 1.63A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 7btf | NSP12 (SARS-CoV-2) | 5 / 8 | LEU A 127ILE A 145LEU A 178THR A 248LEU A 131 | 1.65A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 7btf | NSP8 (SARS-CoV-2) | 5 / 12 | LEU D 169VAL D 186ALA D 188GLU D 155THR D 146 | 1.42A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7btf | NSP12 (SARS-CoV-2) | 4 / 5 | ALA A 250THR A 248VAL A 128ILE A 244 | 1.53A | 16.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 7btf | NSP7NSP8 (SARS-CoV-2) | 5 / 8 | LEU C 56ILE D 106LEU D 103THR C 9LEU C 13 | 1.66A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7btf | NSP8 (SARS-CoV-2) | 4 / 5 | ALA B 102THR B 123VAL B 115ILE B 120 | 1.56A | 19.75 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 205ILE A 259ALA A 260ALA A 266THR A 224 | 1.56A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 4 / 5 | LEU A 271ALA A 266VAL A 212ILE A 259 | 1.57A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 4 / 5 | LEU A 250ALA A 255VAL A 212ILE A 213 | 1.67A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 5 / 9 | LEU A 205ILE A 259ALA A 260ALA A 266THR A 224 | 1.57A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 5 / 9 | LEU A 205VAL A 247ILE A 259ALA A 266THR A 224 | 1.63A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 89PHE A 66VAL A 20LEU A 58ILE A 43 | 1.47A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 4 / 8 | LEU A 208ILE A 281LEU A 287LEU A 268 | 1.25A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 4 / 5 | ALA A 210THR A 257VAL A 261ILE A 259 | 1.40A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 4 / 5 | LEU A 271ALA A 266VAL A 212ILE A 259 | 1.47A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 4 / 5 | LEU A 205THR A 257VAL A 212ILE A 213 | 1.70A | 21.09 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 5 / 9 | LEU A 89PHE A 66VAL A 20LEU A 58ILE A 43 | 1.48A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 8 | LEU A 575LEU A 638THR A 686LEU A 576 | 0.88A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 187LEU A 282ALA A 253THR A 252ALA A 250 | 1.58A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 8 | LEU A 127ILE A 145LEU A 178LEU A 131 | 1.31A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 186ALA A 250THR A 248VAL A 128 | 1.56A | 17.29 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 576ALA A 690VAL A 587ILE A 757 | 1.60A | 17.29 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 146ALA A 130VAL A 182ILE A 244 | 1.44A | 17.29 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7bv1 | NSP8 (SARS-CoV-2) | 4 / 5 | LEU D 169THR D 141VAL D 186ILE D 132 | 1.57A | 19.89 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 7bv1 | NSP8 (SARS-CoV-2) | 5 / 12 | LEU B 169VAL B 186ALA B 188GLU B 155THR B 146 | 1.58A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 7bv1 | NSP12NSP8 (SARS-CoV-2) | 4 / 5 | LEU A 387ALA B 188VAL B 131ILE B 185 | 1.31A | 17.29 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 7bv1 | NSP8 (SARS-CoV-2) | 5 / 5 | LEU B 98ALA B 125THR B 123VAL B 115ILE B 119 | 1.75A | 19.89 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 6 | GLN A 773ALA A 777ALA A 706THR A 710 | 1.70A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 7bv1 | NSP8 (SARS-CoV-2) | 4 / 5 | LEU D 169THR D 141VAL D 186ILE D 132 | 1.50A | 19.89 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 5 | ALA A 250THR A 248VAL A 128ILE A 244 | 1.54A | 17.29 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 7bv1 | NSP8 (SARS-CoV-2) | 4 / 5 | ALA B 102THR B 123VAL B 115ILE B 120 | 1.50A | 19.89 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 329ALA A 379VAL A 359ILE A 333 | 1.45A | 17.29 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 8 | LEU A 245ILE A 244LEU A 241LEU A 186 | 1.16A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 7bv1 | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | LEU B 117VAL A 398ILE B 119ALA B 125THR B 124 | 1.56A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 575ALA A 690VAL A 476ILE A 696 | 1.58A | 17.29 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 7bv1 | NSP7NSP8 (SARS-CoV-2) | 4 / 8 | LEU C 56ILE D 106LEU C 60LEU D 95 | 1.25A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_A_CL6A506_1 (CHOLESTEROL24-HYDROXYLASE) | 7bv1 | NSP8 (SARS-CoV-2) | 5 / 9 | LEU B 169VAL B 186ALA B 188GLU B 155THR B 146 | 1.58A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 5 | ALA A 250THR A 248VAL A 128ILE A 244 | 1.55A | 17.29 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 7bv1 | NSP7NSP8 (SARS-CoV-2) | 5 / 8 | LEU D 103ILE D 107LEU D 95THR C 9LEU D 98 | 1.78A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7bv1 | NSP8 (SARS-CoV-2) | 4 / 5 | ALA D 188THR D 187VAL D 160ILE D 185 | 1.66A | 19.89 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 329ALA A 379VAL A 359ILE A 333 | 1.55A | 17.29 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 883LEU A 891ILE A 888ALA A 863ALA A 840 | 1.54A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 7bv1 | NSP7NSP8 (SARS-CoV-2) | 4 / 8 | LEU D 103ILE D 106LEU C 56LEU D 95 | 1.33A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 186ALA A 250THR A 248VAL A 128 | 1.55A | 17.29 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 5 | ALA A 529THR A 531VAL A 373ILE A 536 | 1.61A | 17.29 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 673THR A 538ILE A 539ALA A 376ALA A 382 | 1.23A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 7bv1 | NSP7NSP8 (SARS-CoV-2) | 4 / 8 | LEU D 95ILE D 107LEU C 56LEU D 91 | 1.11A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 245ALA A 185THR A 189VAL A 234 | 1.67A | 17.29 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 146ALA A 130VAL A 182ILE A 244 | 1.55A | 17.29 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 7bv2 | NSP8 (SARS-CoV-2) | 4 / 5 | ALA B 102THR B 123VAL B 115ILE B 120 | 1.54A | 19.89 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 7bv2 | NSP12NSP8 (SARS-CoV-2) | 4 / 5 | LEU A 387ALA B 188VAL B 131ILE B 185 | 1.31A | 17.29 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 673THR A 538ILE A 539ALA A 376ALA A 382 | 1.36A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7bv2 | NSP8 (SARS-CoV-2) | 4 / 5 | ALA B 102THR B 123VAL B 115ILE B 120 | 1.66A | 19.89 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 282ALA A 250THR A 246VAL A 315 | 1.74A | 17.29 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 146ALA A 130VAL A 182ILE A 244 | 1.55A | 17.29 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 186ALA A 250THR A 248VAL A 128 | 1.72A | 17.29 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 575ALA A 690VAL A 476ILE A 696 | 1.56A | 17.29 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 7bv2 | NSP8 (SARS-CoV-2) | 5 / 5 | LEU B 98ALA B 125THR B 123VAL B 115ILE B 119 | 1.68A | 19.89 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 883PHE A 428LEU A 869ALA A 840ALA A 866 | 1.51A | NoneNoneNone U P 18 ( 3.4A)None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 8 | LEU A 245ILE A 244LEU A 241LEU A 186 | 1.09A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 7bv2 | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | LEU A 372PHE A 368LEU A 514THR B 84ALA B 86 | 1.58A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7bv2 | NSP8 (SARS-CoV-2) | 5 / 5 | LEU B 98ALA B 125THR B 123VAL B 115ILE B 119 | 1.65A | 19.89 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 576ALA A 690VAL A 587ILE A 757 | 1.61A | 17.29 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7bv2 | NSP8 (SARS-CoV-2) | 4 / 5 | LEU B 169ALA B 188VAL B 160ILE B 185 | 1.74A | 19.89 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 6 | GLN A 773ALA A 777ALA A 706THR A 710 | 1.72A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 5 | ALA A 529THR A 531VAL A 373ILE A 536 | 1.61A | 17.29 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 245ALA A 185THR A 189VAL A 234 | 1.60A | 17.29 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 3MDV_B_CL6B506_1 (CHOLESTEROL24-HYDROXYLASE) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 187LEU A 282ALA A 253THR A 252ALA A 250 | 1.57A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 575ALA A 690VAL A 476ILE A 696 | 1.68A | 17.29 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 245ALA A 185THR A 189VAL A 234 | 1.64A | 17.29 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1413_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 6 | HIS A 133ALA A 46ALA A 34THR A 123 | 1.54A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 5 | ALA A 250THR A 248VAL A 128ILE A 244 | 1.59A | 17.29 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_A_CL6A502_1 (CYTOCHROME P-450) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 5 | ALA A 706THR A 710VAL A 720ILE A 715 | 1.72A | 17.29 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 2XFH_A_CL6A1414_1 (ERYTHROMYCIN B/DC-12 HYDROXYLASE) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 8 | LEU A 575LEU A 638THR A 686LEU A 576 | 0.97A | None | |||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 5 | ALA A 250THR A 248VAL A 128ILE A 244 | 1.59A | 17.29 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4XE3_B_CL6B502_1 (CYTOCHROME P-450) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 5 | LEU A 146ALA A 130VAL A 182ILE A 244 | 1.45A | 17.29 | None |